Coumarin and 7-hydroxycoumarin treatment of canine obstructive lymphoedema.
Identifieur interne : 007C39 ( Ncbi/Curation ); précédent : 007C38; suivant : 007C40Coumarin and 7-hydroxycoumarin treatment of canine obstructive lymphoedema.
Auteurs : K R Knight [Australie] ; R K Khazanchi ; W C Pederson ; J J Mccann ; S A Coe ; B M O'BrienSource :
- Clinical science (London, England : 1979) [ 0143-5221 ] ; 1989.
Descripteurs français
- KwdFr :
- MESH :
- analyse : Protéines.
- anatomopathologie : Lymphoedème, Peau.
- métabolisme : Endopeptidases, Lymphe.
- traitement médicamenteux : Lymphoedème.
- usage thérapeutique : Coumarines, Ombelliférones.
- Animaux, Chiens, Membre pelvien.
English descriptors
- KwdEn :
- MESH :
- chemical , analysis : Proteins.
- chemical , metabolism : Endopeptidases.
- chemical , therapeutic use : Coumarins, Umbelliferones.
- drug therapy : Lymphedema.
- metabolism : Lymph.
- pathology : Lymphedema, Skin.
- Animals, Dogs, Hindlimb.
Abstract
1. Canine obstructive lymphoedema was created in one hind leg of 30 dogs by irradiation of the groin and surgical removal of surviving lymph glands and lymphatics. The opposite leg served as a control. Once the oedema had stabilized, groups of 10 dogs were treated orally with 12.5 mg day-1 kg-1 for 8 months with either one of the benzopyrones coumarin (2H-1-benzopyran-2-one) and 7-hydroxycoumarin (7-hydroxy-2H-1-benzopyran-2-one), or placebo. 2. The two benzopyrones significantly (P less than 0.01) but gradually reduced the oedema by 20-30% over 8 months, as judged by circumferential measurements of the oedematous and control limbs. There was no change with the placebo. 3. In the oedematous fluids (lymph and interstitial fluid), benzopyrone treatment reduced the protein content and increased acid and neutral proteinase activity compared with the control limbs, while the levels of the proteinase inhibitor alpha 2-macroglobulin remained unchanged. Furthermore, these active drugs reduced the excess water content, thickness and hydroxyproline content of skin biopsies from oedematous limbs compared with those from control limbs. No changes were observed for the placebo group. 4. These biochemical changes suggest that benzopyrones can reduce the excess proteinaceous fluid in lymphoedema by increasing the levels of proteinase activity relative to the number of proteinase inhibitors. As a secondary event the amount of fibrosis in the skin is also reduced, presumably by an increase in collagenase activity from the mononuclear phagocytes. 5. These results support the hypothesis that benzopyrones activate the production of proteinases by mononuclear phagocytes.(ABSTRACT TRUNCATED AT 250 WORDS)
PubMed: 2667858
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005F66
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :005F66
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :005F66
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :007C39
Links to Exploration step
pubmed:2667858Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coumarin and 7-hydroxycoumarin treatment of canine obstructive lymphoedema.</title><author><name sortKey="Knight, K R" sort="Knight, K R" uniqKey="Knight K" first="K R" last="Knight">K R Knight</name><affiliation wicri:level="1"><nlm:affiliation>Microsurgery Research Centre, St Vincent's Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Microsurgery Research Centre, St Vincent's Hospital, Melbourne</wicri:regionArea><wicri:noRegion>Melbourne</wicri:noRegion></affiliation></author><author><name sortKey="Khazanchi, R K" sort="Khazanchi, R K" uniqKey="Khazanchi R" first="R K" last="Khazanchi">R K Khazanchi</name></author><author><name sortKey="Pederson, W C" sort="Pederson, W C" uniqKey="Pederson W" first="W C" last="Pederson">W C Pederson</name></author><author><name sortKey="Mccann, J J" sort="Mccann, J J" uniqKey="Mccann J" first="J J" last="Mccann">J J Mccann</name></author><author><name sortKey="Coe, S A" sort="Coe, S A" uniqKey="Coe S" first="S A" last="Coe">S A Coe</name></author><author><name sortKey="O Brien, B M" sort="O Brien, B M" uniqKey="O Brien B" first="B M" last="O'Brien">B M O'Brien</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1989">1989</date><idno type="RBID">pubmed:2667858</idno><idno type="pmid">2667858</idno><idno type="wicri:Area/PubMed/Corpus">005F66</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005F66</idno><idno type="wicri:Area/PubMed/Curation">005F66</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005F66</idno><idno type="wicri:Area/PubMed/Checkpoint">005F66</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005F66</idno><idno type="wicri:Area/Ncbi/Merge">007C39</idno><idno type="wicri:Area/Ncbi/Curation">007C39</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Coumarin and 7-hydroxycoumarin treatment of canine obstructive lymphoedema.</title><author><name sortKey="Knight, K R" sort="Knight, K R" uniqKey="Knight K" first="K R" last="Knight">K R Knight</name><affiliation wicri:level="1"><nlm:affiliation>Microsurgery Research Centre, St Vincent's Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Microsurgery Research Centre, St Vincent's Hospital, Melbourne</wicri:regionArea><wicri:noRegion>Melbourne</wicri:noRegion></affiliation></author><author><name sortKey="Khazanchi, R K" sort="Khazanchi, R K" uniqKey="Khazanchi R" first="R K" last="Khazanchi">R K Khazanchi</name></author><author><name sortKey="Pederson, W C" sort="Pederson, W C" uniqKey="Pederson W" first="W C" last="Pederson">W C Pederson</name></author><author><name sortKey="Mccann, J J" sort="Mccann, J J" uniqKey="Mccann J" first="J J" last="Mccann">J J Mccann</name></author><author><name sortKey="Coe, S A" sort="Coe, S A" uniqKey="Coe S" first="S A" last="Coe">S A Coe</name></author><author><name sortKey="O Brien, B M" sort="O Brien, B M" uniqKey="O Brien B" first="B M" last="O'Brien">B M O'Brien</name></author></analytic><series><title level="j">Clinical science (London, England : 1979)</title><idno type="ISSN">0143-5221</idno><imprint><date when="1989" type="published">1989</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Coumarins (therapeutic use)</term><term>Dogs</term><term>Endopeptidases (metabolism)</term><term>Hindlimb</term><term>Lymph (metabolism)</term><term>Lymphedema (drug therapy)</term><term>Lymphedema (pathology)</term><term>Proteins (analysis)</term><term>Skin (pathology)</term><term>Umbelliferones (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Chiens</term><term>Coumarines (usage thérapeutique)</term><term>Endopeptidases (métabolisme)</term><term>Lymphe (métabolisme)</term><term>Lymphoedème (anatomopathologie)</term><term>Lymphoedème (traitement médicamenteux)</term><term>Membre pelvien</term><term>Ombelliférones (usage thérapeutique)</term><term>Peau (anatomopathologie)</term><term>Protéines (analyse)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Endopeptidases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Coumarins</term><term>Umbelliferones</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Protéines</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Lymphoedème</term><term>Peau</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lymph</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Endopeptidases</term><term>Lymphe</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lymphedema</term><term>Skin</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Coumarines</term><term>Ombelliférones</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Dogs</term><term>Hindlimb</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Chiens</term><term>Membre pelvien</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">1. Canine obstructive lymphoedema was created in one hind leg of 30 dogs by irradiation of the groin and surgical removal of surviving lymph glands and lymphatics. The opposite leg served as a control. Once the oedema had stabilized, groups of 10 dogs were treated orally with 12.5 mg day-1 kg-1 for 8 months with either one of the benzopyrones coumarin (2H-1-benzopyran-2-one) and 7-hydroxycoumarin (7-hydroxy-2H-1-benzopyran-2-one), or placebo. 2. The two benzopyrones significantly (P less than 0.01) but gradually reduced the oedema by 20-30% over 8 months, as judged by circumferential measurements of the oedematous and control limbs. There was no change with the placebo. 3. In the oedematous fluids (lymph and interstitial fluid), benzopyrone treatment reduced the protein content and increased acid and neutral proteinase activity compared with the control limbs, while the levels of the proteinase inhibitor alpha 2-macroglobulin remained unchanged. Furthermore, these active drugs reduced the excess water content, thickness and hydroxyproline content of skin biopsies from oedematous limbs compared with those from control limbs. No changes were observed for the placebo group. 4. These biochemical changes suggest that benzopyrones can reduce the excess proteinaceous fluid in lymphoedema by increasing the levels of proteinase activity relative to the number of proteinase inhibitors. As a secondary event the amount of fibrosis in the skin is also reduced, presumably by an increase in collagenase activity from the mononuclear phagocytes. 5. These results support the hypothesis that benzopyrones activate the production of proteinases by mononuclear phagocytes.(ABSTRACT TRUNCATED AT 250 WORDS)</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007C39 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 007C39 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:2667858
|texte= Coumarin and 7-hydroxycoumarin treatment of canine obstructive lymphoedema.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:2667858" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |